Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for diabetes and weight management research. This 39-amino acid peptide features two non-natural residues and a C20 fatty diacid side chain, providing an extended half-life of approximately 117 hours.
Our facility produces pharmaceutical-grade tirzepatide with 99% purity, available in various dosages from 5mg to 60mg vials. The compound mimics endogenous incretins to enhance insulin secretion, suppress glucagon levels, delay gastric emptying, and reduce appetite - making it valuable for metabolic research.
For research protocols, the recommended dosage regimen begins with 2.5mg administered subcutaneously once weekly, with potential escalation to 5mg after 4 weeks. Maximum research doses typically reach 15mg weekly. Our production follows strict GMP standards with multi-step quality testing including HPLC and mass spectrometry.
As a specialized peptide manufacturer, we offer:
Note: This product is for research use only, not for human consumption. Proper handling procedures should be followed by qualified researchers.